| Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′ s main protease M Mahdi, JA Mótyán, ZI Szojka, M Golda, M Miczi, J Tőzsér Virology journal 17, 1-8, 2020 | 101 | 2020 |
| Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease JA Mótyán, M Mahdi, G Hoffka, J Tőzsér International journal of molecular sciences 23 (7), 3507, 2022 | 55 | 2022 |
| Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19 M Mahdi, L Hermán, JM Réthelyi, BL Bálint International Journal of Molecular Sciences 23 (7), 3812, 2022 | 31 | 2022 |
| Functional study of the retrotransposon-derived human PEG10 protease M Golda, JA Mótyán, M Mahdi, J Tőzsér International Journal of Molecular Sciences 21 (7), 2424, 2020 | 21 | 2020 |
| Inhibition profiling of retroviral protease inhibitors using an HIV-2 modular system M Mahdi, Z Szojka, JA Mótyán, J Tőzsér Viruses 7 (12), 6152-6162, 2015 | 19 | 2015 |
| Inhibitory effects of HIV-2 Vpx on replication of HIV-1 M Mahdi, Z Szojka, JA Mótyán, J Tőzsér Journal of Virology 92 (14), 10.1128/jvi. 00554-18, 2018 | 14 | 2018 |
| Cellular proteo-transcriptomic changes in the immediate early-phase of lentiviral transduction TR Linkner, V Ambrus, B Kunkli, ZI Szojka, G Kalló, É Csősz, A Kumar, ... Microorganisms 9 (11), 2207, 2021 | 13 | 2021 |
| Analysis of networks of host proteins in the early time points following HIV transduction É Csősz, F Tóth, M Mahdi, G Tsaprailis, M Emri, J Tőzsér BMC bioinformatics 20, 1-18, 2019 | 10 | 2019 |
| A modular system to evaluate the efficacy of protease inhibitors against HIV-2 M Mahdi, K Matúz, F Tóth, J Tőzsér PLoS One 9 (11), e113221, 2014 | 10 | 2014 |
| Monocytes in neonatal immunity M Mahdi, L Maródi NeoReviews 11 (10), e558-e565, 2010 | 5 | 2010 |
| Nijmegen Breakage syndrome M Erdős, B Tóth, P Juhász, M Mahdi, L Maródi Orvosi Hetilap 151 (16), 665-673, 2010 | 4 | 2010 |
| Fabry-betegség–terápiás útmutató T Constantin, A Székely, A Ponyi, V Gulácsy, C Ambrus, K Kádár, ... | 4 | 2010 |
| Clinical spectrum and CSF findings in patients with West-Nile virus infection, a retrospective cohort review I Bakos, M Mahdi, L Kardos, A Nagy, I Várkonyi Diagnostics 12 (4), 805, 2022 | 3 | 2022 |
| Management of Fabry disease T Constantin, A Székely, A Ponyi, V Gulácsy, C Ambrus, K Kádár, ... Orvosi Hetilap 151 (31), 1243-1251, 2010 | 3 | 2010 |
| Identification of SARS-CoV-2 Main protease (Mpro) cleavage sites using two-dimensional electrophoresis and in silico cleavage site prediction N Miltner, G Kalló, É Csősz, M Miczi, T Nagy, M Mahdi, JA Mótyán, ... International Journal of Molecular Sciences 24 (4), 3236, 2023 | 2 | 2023 |
| Aspects of the endothelin system in colorectal cancer MR Mahdi, RF Bedeer, HM Eltahry, MR Berger Biomedical Reviews 25, 1-13, 2014 | 2 | 2014 |
| Fabry disease diagnostic guideline T Constantin, É Rákóczi, A Ponyi, C Ambrus, K Kádár, I Vastagh, ... Orvosi Hetilap 151 (7), 243-249, 2010 | 2 | 2010 |
| The PARP inhibitor rucaparib blocks SARS‐CoV‐2 virus binding to cells and the immune reaction in models of COVID‐19 H Papp, E Tóth, J Bóvári‐Biri, K Bánfai, P Juhász, M Mahdi, LC Russo, ... British Journal of Pharmacology, 2024 | 1 | 2024 |
| Early suppression of antiviral host response and protocadherins by SARS-CoV-2 Spike protein in THP-1-derived macrophage-like cells N Miltner, TR Linkner, V Ambrus, AS Al-Muffti, H Ahmad, JA Motyan, ... Frontiers in Immunology 13, 999233, 2022 | 1 | 2022 |
| Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2 IW Kiarie, G Hoffka, M Laporte, P Leyssen, J Neyts, J Tőzsér, M Mahdi Preprints, 2024 | | 2024 |
